National Forum urges CMS to ensure that payers do not reduce access to price-negotiated, evidence-based medications that are helping Medicare beneficiaries manage heart disease and stroke risk factors and conditions.
Read our comments on Medicare Drug Price Negotiation Draft Guidance.
